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Summary The studv was designed to insvestigate possible relationships between tumour response and exposure
to cisplatin (area under the curve of unbound cisplatin in plasma. AUC) and DNA-adduct formation in
leucocytes (WBC) in patients with solid tumours. Patients were treated with six weekly courses of cisplatin at a
dose of 70 or 80 mg m-. The AUC was determined during the first course and DNA-adduct levels in WBC
during all courses at baseline, 1 h (A,) and 15 h after a 3 h infusion of cisplatin. The area under the DNA-
adduct-time curve (AUA) was calculated. The tumour response was determined after six courses. Forty-five
esvaluable patients received 237 courses of cisplatin. Sixteen patients with head and neck cancer received a dose
of 80 mg m and 29 with various other tumour types received 70 mg m - plus daily 50 mg oral etoposide.
There were 20 responders (partial and complete) and 25 non-responders (stable and progressiv-e disease). The
AUC was highly sariable (mean+s.d.=2.48+0.51 pu h 'ml-; range 1.10-3.82) and was closely correlated
with the AUA (r=0.78. P<0.0001) and Ama_ (r=0.73. P<0.0001). The AUC. AUA and A w,,, were
significantlv higher in responders than in non-responders in the total population (P<0.0001) and in the two
subgroups treated at 70 or 80 mg m- . In logistic regression analysis AUC. AUA and A, were important
predictors of response. The magnitude of exposure to cisplatin is. through DNA-adduct formation. the major
determinant of the response rate in this population. Hence. individualised dosing of cisplatin using AUC or
DNA-adducts should lead to increased response rates.
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Cisplatin is considered the most active drug in testicular and
ovarian cancer (Loehrer and Einhorn. 1984: Motzer et al..
1988; Ozols et al.. 1988: Kaye et al.. 1992: Bajorin et al..
1993; Levin et al.. 1993: Stoter et al.. 1996) and it has
considerable activity against several other solid tumours
(Alberts et al.. 1991; Glover et al.. 1987: Stoter et al.. 1987:
Hansen. 1992: Slotman et al.. 1992: Hainsworth and Greco.
1993: Krarup-Hansen and Hansen. 1991; Planting et al..
1993b: Paccagnella et al.. 1994: Roth et al.. 1994: Planting et
al.. 1994). The clinical application of cisplatin is limited
however by the existence or development of resistance and
the induction of severe side-effects (Loehrer and Einhorn.
1984: Eastman and Schulte. 1988: Daugaard and Abildgaard.
1989: Ozols. 1989: Cavaletti et al.. 1992: Siegal and Haim.
1990).
It is common practice to dose cisplatin per m body
surface area. However. this strategy results in wide
interpatient differences in the magnitude of exposure to
cisplatin. i.e. the area under the concentration-time curve
(AUC) in plasma or tissues (Himmelstein et al.. 1981: Reece
et al.. 1987. 1989). Importantly. several clinical studies in
ovarian and testicular cancer clearly established significant
relationships between dose. dose intensity and total delivered
dose on the one hand and tumour response rate and side-
effects on the other (Ozols et al.. 1988: Kaye et al.. 1992:
Levin et al.. 1993: Ozols, 1989: Bruckner et al.. 1981: Samson
et al.. 1984: Levin and Hryniuk. 1987: Markman. 1993).
Interpatient differences in the dose -response and dose-
toxicity relationship can be explained by interpatient
differences in the dose-AUC relationship by pharmacody-
namic variability. or by both.
For the cisplatin analogue carboplatin. retrospective
analyses in ovarian and testicular cancer revealed sigificant
relationships betw een the AUC and the likelihood of a
tumour response (Jodrell et al.. 1992: Childs et al.. 1992).
Earlier studies revealed that the AUC was predictive of the
dose-limiting thrombocytopenia (Calvert et al.. 1982: Egorin
et al.. 1984). This. combined with the close correlation
between renal function and the AUC of carboplatin has lead
to the clinical application of practical methods to individ-
ualise carboplatin treatment (Childs et al.. 1992: Egorin et al..
1985: Calvert et al.. 1989).
The cytotoxicity of cisplatin is most closely correlated with
its covalent binding to nuclear DNA. so-called cross-links or
adducts (Eastman. 1986: Reed et al.. 1986. 1987: Fichtinger-
Schepman et al.. 1987). For practical reasons DNA-adducts
have been frequently quantitated in WBC (Reed et al., 1986.
1987: Fichtinger-Schepman et al.. 1987: Reed et al.. 1993:
Parker et al.. 1991: Hengstler et al.. 1992: Motzer et al..
1994). Clinical studies with cisplatin and carboplatin in
various types of solid tumours revealed significantly higher
DNA-adduct levels in WBC and buccal cells in responders
than in non-responders (Reed et al.. 1986. 1993: Parker et al..
1991: Hengstler et al.. 1992: Reed et al.. 1988a. 1990: Gill et
al.. 1991: Blommaert et al.. 1993). DNA-adduct levels in
tumour tissue were correlated with the levels in healthy
tissues (Poirier et al.. 1992). Of note. no significant
relationships have been established between the AUC of
cisplatin and the DNA-adduct formation (Reed et al.. 1988a).
We hy-pothesised that the likelihood of a tumour response
in potentially sensitive tumours and interindividual variation
in the formation of DNA-adducts in WBC are dominated by
interpatient differences in the magnitude of exposure to
active. i.e. non-protein bound. cisplatin. We tested this
hypothesis prospectively in a patient population with various
types of solid tumours with potential sensitivity for cisplatin.
Methods
Selection ofpatients and treatment schedule
All patients gave informed consent according to local
regulatory requirements. Eligibility for the study required a
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pathologically confirmed cancer not curable by surgery,
radiotherapy or chemotherapy and with potential sensitivity
for cisplatin, such as head and neck cancer (H/N),
mesothelioma, non-small-cell lung cancer (NSCLC), melano-
ma, cervix cancer and adenocarcinoma of unknown primary
site (ACUP).
The performance status had to be <2 on the WHO scale
(World Health Organization, 1979), life expectancy > 3
months and the age between 18 and 75 years. No previous
chemotherapy with cisplatin or carboplatin was allowed and
no radiotherapy for at least 4 weeks before entry in the study.
Lesions had to be measurable according to WHO criteria
(World Health Organization, 1979). Each patient had a
complete medical history and physical and neurological
examination, complete blood count and determination of
serum chemistries including albumin, total protein, electro-
lytes, blood urea nitrogen (BUN), creatinine and complete
liver function tests. The creatinine clearance was determined
before each administration of cisplatin using the serum
creatinine and 24 h urinary creatinine excretion.
Neurological evaluation was carried out as described
previously (Goldberg and Lindblom, 1979; Gerritsen Van
Der Hoop et al., 1990) before entry in the study, at 2 weeks
and at 3 and 6 months after the end of the cisplatin therapy.
Briefly, the severity of neuropathy was evaluated by a
questionnaire of neurological symptoms, by performing a
sensory neurological examination and by measurement of the
vibration perception threshold (VPT).
All patients had to have adequate renal and liver function,
i.e. serum creatinine < 1.4 mg dl-' (120 pmol 1-') or clear-
ance )60mlmin-1 and serum bilirubin <1.5mgdl-'
(25 umol 1-), WBC)3.0x 109 1-1 and platelet count
>I100 xlW1-'. The tumour response was scored after six
courses as complete (CR) or partial response (PR), stable
disease (SD) or progressive disease (PD). CR and PR were
grouped as responders and SD and PD as non-responders.
The response was determined earlier during treatment if there
was any indication of early progressive disease. Toxicity was
scored according to the common toxicity criteria (National
Cancer Institute, 1988). Complete blood count, serum
chemistries, urinalysis and determination of the creatinine
clearance were repeated weekly.
Head and neck cancer was treated with weekly courses of
cisplatin at a dose of 80 mg m-2 on days 1, 8, 15, 22, 29
and 36 according to a previously established schedule
(Planting et al., 1993a). The treatment was used as an
induction regimen, preceding surgery and/or radiotherapy.
All other tumour types were treated with weekly cisplatin at
a dose of 70 mg m-2 on days 1, 8, 15, 29, 36 and 43 plus
50mg of oral etoposide from day 1-15 and 29-43
according to a previously established schedule (Planting et
al., 1991, 1994). In the latter group, in case of a response
etoposide was to be continued thereafter for up to four
cycles at an oral dose of 50 mg m-2 from day 1-21 every 4
weeks. Cisplatin was dissolved in 250 ml of 3% sodium
chloride and administered as a 3 h infusion with standard
pre- and post-hydration.
Pharmacological studies
Sample collection During the first course heparinised blood
samples were collected at 0, 1, 2, 3, 4, 6, 8 and 18 h after start
of the infusion. The samples were of 4 ml each except at 0, 4
and 18 h which were of 16 ml each. During all subsequent
course samples of 16 ml were collected at 0, 4 and 18 h after
start of the infusion with cisplatin. During the first course all
urine was collected up to 24 h after start of the infusion with
cisplatin.
Analysis of cisplatin in plasma and DNA-adduct levels in
WBC Total and non-protein bound cisplatin and the total
DNA-adduct levels of cisplatin were determined with atomic
spectroscopy (AAS) according to the method of Reed et al.
(1988b), with modifications (Ma et al., 1995).
Data analysis The area under the plasma concentration-
time curve (AUC jg h `ml-1) of unbound cisplatin
[measured with AAS as platinum (Pt)] was determined with
extended least squares regression analysis (Sheiner and Beal,
1985). Plasma clearance (Cl) of unbound cisplatin was
calculated by dose/AUC (ml min-'). The terminal half-life
of unbound cisplatin was calculated by 1n2/k (min), where k
is the rate constant of the terminal phase. The renal clearance
of cisplatin was calculated by multiplying the fraction of the
dose of cisplatin excreted in the urine by the Cl of unbound
cisplatin. The DNA-adduct level 1 h after infusion was
denoted A.. (Ma et al., 1995) and expressed as picogram of
platinum per pg DNA (pg Pt pg-'DNA). The area under the
DNA-adduct-time curve (AUA, pg Pt h pg-'DNA) was
calculated up to 15 h after infusion with the trapezoidal
method, using the three DNA-adduct-time points (Figure 1).
The Siphar software package was used for pharmacological
calculations version (4.0, SIMED, Creteil, Cedex, France).
Statistical analysis Linear regression analysis and Pearson
correlation analysis were used to quantitate the relationship
between AUC and AUA and AUC and Am.. The Pearson
correlation coefficient was used for calculation of the
correlation between the creatinine clearance and the renal
and plasma clearance of cisplatin. The unpaired two-sided
Student's t-test was used to test for differences between
responders and non-responders in A,,,., AUA and AUC. In
addition, this test was used to assess any significant
differences in AUC, plasma clearance and terminal half-life
of unbound cisplatin and AUA and A,,,. between the two
subgroups who were treated with 70 or 80 mg m-2.
Logistic regression analysis (Hosmer and Lemeshow, 1989)
was applied to establish the relationship between AUC, as
well as AUA and A,,., and the likelihood of a response. The
equation can be written as:
Likelihood of a response= {1 +expdA +B*X)]}-I
where the dependent parameter is the likelihood of a tumour
response, A and B are coefficients and X is the independent
parameter (AUC, AUA or Am). Goodness-of-fit of each
logistic model was assessed with the Hosmer-Lemeshow test
(Hosmer and Lemeshow, 1980).
The Pearson and Spearman rank correlation coefficient
and chi-square test were applied to test for relationships
between myelosuppression, renal and neurotoxicity and
AUC, AUA and A,.. For statistical analysis of neurotoxi-
city the maximal sum score post-treatment of the neurologi-
cal questionnaire and sensory examination were used, as well
as the logarithm of the maximal VPT post treatment (log
VPT).
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Figure 1 DNA-adduct-time curve ofcisplatin during six weekly
courses of 70-80mgm-2 in 45 patients (mean+s.d.). The DNA-
adduct-time-points (0) per course were: baseline, 1h and 15h
after infusion. Shaded area, area under the DNA-adduct-time
curve (AUA), cakulated using the three time points and the
trapezoidal method.Cisplatin exposure and keIIhood of t=xKw response
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Multiple linear regression analysis was used to test for
differences in the AUC-AUA relationship (i.e. exposure to
cisplatin and DNA-adduct formation) between the two
subgroups treated with 70 or 80 mg m- of cisplatin. The
statistical analysis was carried out by application of Stata
(version 3.1, Statistics Data Analysis. Computing Resourse
Center. Santa Monica. CA. USA).
Results
Population demographics
Patient demographic characteristics are shown in Table I. A
total of 50 eligible patients were entered in the study. Eight
patients had previously received radiotherapy and two
patients chemotherapy. One received isolated regional limb
perfusion with melphalan for melanoma 4 years before entry
into the study and one had systemic cyclophosphamide for
adenocarcinoma of unknown primary site 5 years before
entry. Five patients were not evaluable for tumour response.
Three of the non-evaluable patients developed renal toxicity
(two patients grade 1 and one grade 3. after one. two and
one course, respectively) preventing further treatment. One
patient stopped because of grade 3 gastrointestinal toxicity
after four courses and one patient refused further treatment
after two courses. Data of these five patients were included
in the evaluation of renal toxicity. The 45 patients who were
evaluable for response received a total of 237 courses. All
patients received at least one course and were followed for
at least 3 months. The mean number of courses per patient
was 5.3 (88% of planned). The dose-intensity in the
subgroup treated at 70 mg m- cisplatin plus VP16 was
53.5 mg m-2 week-' (89% of planned) and in the subgroup
treated at 80 mg m` cisplatin as single agent
71.2 mg m - week-' (89% of planned). Overall there were
20 responders (44%: two CRs and 18 PRs) and 25 non-
responders (56%0 16 SD and 9 PD). In the subgroup with
cisplatin and VP16 there were 10 responders (34%0 all PR)
and 19 non-responders (66%; 12 SD and 7 PD).
Pharmacokinetics. DNA-adduct formation and tumour
response
The AUC ofunbound cisplatin showed substantial interpatient
vranability (Table II). The AUC varied from 1.1 -
3.82 Mg h-' ml-' and the coefficient of variation (%CV) was
210%. The plasma clearance of unbound cisplatin was
635+217 ml min-' (range 312-1477) and the half-life
38 +10 mn (range 23-72). The volume of distribution of
unbound cisplatin was 34+ 13 1 (range 15 -86). The renal
clearance quantitated using the first 24 h urine portion was
167+ 71 ml min-1 (range 102 -338). The correlation coefficient
between the creatinine clearance and renal clearance of
unbound cisplatin was 0.70 (P<0.01. n=20). between
creatinine clearance and plasma clearance of unbound
cisplatin 0.46 (P<0.01. n= 20) and between renal and plasma
clearance of unbound cisplatin 0.92 (P<0.00001. n = 50).
Also the AUA and A,,, vanred considerably (Table II).
The %CV of the first course AUA was 25% and of the A,4,
27%. The variability of the AUA and A,,,, during the
subsequent courses was of the same order as during the first
course.
There was a highlv sinificant correlation between the
AUC and the AUA and A, The correlation coefficient was
0.78 (P<0.0001. n=45) between AUC and AUA (Figure 2)
and 0.73 (P<0.0001) between AUC and A,,,. Of note. there
was no significant correlation between the absolute dose
given and the AUC (r=0.1. P=0.53). No significant
correlations were observed between the kinetics of total. i.e.
bound plus unbound cisplatin and DNA-adduct formation
(AUA and A,).
The AUC. AUA and Ax,were significantlv higher in
responders than in non-responders (Table II. Figure 3). This
was evident in the total population as well as in the two
subgroups treated with cisplatin at a dose of 70 mg m-
(various tumour types) and 80 mg m-2 (H N). In addition.
the mean value of the AUA and Am,x of all administered
courses was also significantlv higher in responders than in
non-responders. The AUC in the subgroup treated at
80 mg m-' of cisplatin (2.85+0.55 pg h-' ml-') was signifi-
cantly higher than in the subgroup treated at 70 mg m
(2.28 +0.54 jpg h ml 'p=0.002). The AUA and A,,, were
also significantly higher in the 80 mg m-2 subgroup as a
result of the dose difference. VP16 did not appear to influence
the pharmacokinetics of cisplatin. as there were no
statisticallN significant differences between the two treatment
groups in plasma clearance. renal clearance or terminal half-
life of cisplatin. In addition. VP16 did not affect the DNA-
adduct formation significantlv. as reflected by the slope of the
linear regression relationship between AUC and AUA. xx-hich
Table I Patient characteristics
Characteristic
Total entered
Male
Female
Median age. years (range)
Median performance
scorea (range)
Prior therapy
Chemotherapy
Radiation therapy
Chemotherapy and radiation
None
Diagnosis
Head and neck
Mesothelioma
N-SCLC
ACUP
Cervix
Melanoma
Cisplatin 70 mg m-2
- VP16
24
6
Cisplatin
80mgm--
16
4
.411
40
10
61 (39-70) 53 (44-73) 59 (39-73)
1 (0-2)
12
10
6
1
1
1 (1-2)
0
0
17
2O
1 (0-2)
8
1
40
20
12
10
6
l
I
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aPerformance score according to WHO criteria. N-SCLC. non-small-cell lung cancer:
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Table II Pharmacological parameters ofcilatin in 45 patients treated with six weekly courses of70mgm2 + oral VP16 daily 50 or
8Omgm-2 of ciplatin as single agent
AUC A,., Ist A,.o 1-6 AUA Ist AUA 1-6
Patients Response n (pughml-') (pgPtpg-' DNA) (pgPtug-' DNA) (pgPthug-1 DNA) (pgPthug-' DNA)
Cisplatin Yes 10 2.64+0.40 1.21 +0.28 1.55+0.28 20.0+3.7 23.5-4.6
+ VP16 2.16-3.22 0.84-1.61 1.19-1.90 15.3-25.6 16.1-28.0
No 19 2.08+0.51 0.78+0.19 1.32+0.24 13.0+2.9 18.8+3.1
1.10-3.16 0.34-1.15 0.69-2.30 8.0- 19.5 10.8-33.1
P 0.006 <10-4 0.03 <10-4 0.003
Cisplatin Yes 10 3.09+0.53 1.58+0.26 1.95+0.28 25.3+4.2 30.4+3.8
2.30-3.82 1.10- 1.81 1.60-2.67 17.2-32.4 24.9-37.9
No 6 2.47+0.45 0.92+0.22 1.49+0.43 16.6+4.5 24.3+6.1
2.16-2.88 0.58-1.15 1.07-1.52 10.3-21.3 14.5-26.5
P 0.03 0.0001 0.02 0.001 0.03
All Yes 20 2.86+0.51 1.38+0.36 1.75+0.34 22.6+5.1 27.0+5.4
2.16-3.82 0.64-1.81 1.24-2.67 11.5-32.1 16.1-37.9
No 25 2.17+0.51 0.81+0.21 1.36+0.30 13.7+3.8 20.1+4.5
1.10-3.16 0.34- 1.15 0.69-2.30 7.4-21.3 10.8-33.1
p < 10-4 < o1-7 0.0001 <10-7 < 10-4
Means+s.d. and range are given.
AUC, area underunboundcisplatin plasma concentration-time curve; Am.,cisplatin-DNA-adduct level inWBC 1 hafter 3hinfusion;
AUA, areaundercisplatin-DNA-adduct-time curveinWBC (0- 18h); 1st, first courseofcisplatin; 1-6, Meanofallcourses; response, CR
+ PR; no response, SD + PD.
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Figre 2 Relationship between the magnitude of exposure to
unbound cisplatin (AUC) and AUA during the first course of
cisplatin (r=0.78, P<0.0001). *, response; 0, non-response.
was not significantly different between the two subgroups
treated with and without VP16 (P>0.2). An influence of
VP16 on the DNA-adduct formation could not be tested
directly, because the two subgroups did receive a different
dose of cisplatin.
Logistic regression analysis
Logistic regression analysis revealed highly significant
sigmoid relationships between AUC, AUA and Am., and
the likelihood of a response. This was evident in the total
population and in the subgroup treated with 70 mg m-2 of
cisplatin (P-value of coefficients A and B <0.01 for the total
population of 45 patients and <0.02 in the subgroup of
cisplatin+VP16). The corresponding P-values of the good-
ness-of-fit tests were all >0.50, indicating good fits. The
likelihood of a response reached 100% in the three
relationships with AUC, AUA and A,.
Pharnacokinetics, DNA-adduct formation and toxicity
Myelosuppression was the most frequently encountered side-
effect. CTC grade 1 anaemia was observed in 9 of 45
evaluable patients (20%), grade 2 in 26 (58%) and grade 3 in
AUA AUC
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Figre 3 Area under the DNA-adduct-time curve (AUA) and
area under the plasma concentration -time curves (AUC) in
responders and non-responders to cisplatin chemotherapy.
six patients (13%). Grade 1 leucopenia was observed in 11
patients (24%), grade 2 in nine (20%), grade 3 in 16 (35%)
and grade 4 in one patient (2%). Grade 1 thrombocytopenia
was found in four patients (9%), grade 2 in ten (22%), grade
3 in four (9%) and grade 4 in two patients (4%). The AUC
and AUA were significantly correlated with the CTC grade of
thrombocytopenia [Spearman rank r=0.38, P=0.01 (AUC);
r=0.43 P=0.005 (AUA), n=45]. These relationships were
also significant in the subgroup treated with cisplatin as single
agent, hence without the influence of VP16. In this subgroup
the correleation coefficient between AUC and thrombocyto-
penia was 0.62 (P=0.02, n= 16) and AUA and thrombocy-
topenia 0.70 (P=0.007). The correlation coefficient between
dose m-2 or absolute dose given and thrombocytopenia was
not significant (P=0.11). Correlation coefficients between
AUC/AUA and anaemia or leucocytopenia were not
statistically significant.
Eight patients developed grade 1 nephrotoxicity (16% of
50 patients), one grade 2 (2%) and one patient grade 3 (2%).
No significant Spearman rank correlation coefficients were
observed between AUC, AUA or absolute dose given and
CTC grade of nephrotoxicity (n= 50).
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Forty-five patients were evaluable for the sum score of
neurotoxicity and in 21 patients the log VPT was determined.
Fifteen patients developed grade 1 neurotoxicity (33%). No
grade 2 or higher was observed. The log VPT vanred between
-0.05 and 0.65 (mean 0.23 and s.d. 0.21). No significant
correlation was observed between the cumulative dose nor
dose m-2 and sum score or log VPT. The cumulative AUC
(i.e. AUC of course 1 times number of administered courses)
was significantly correlated with the log VPT (Spearman rank
r=0.52. P=0.01). The AUA and cumulative AUA were not
significantly correlated with the log VPT (P=0.63).
Discussion
For our pharmacological analyses. we applied a dose-
intensive schedule of weekly cisplatin that was previously
developed in our department. Presently over 200 patients
with solid tumours have been treated in phase I II trials
according to this schedule (Planting et al., 1991. 1993a. b.
1994). The importance of the weekly administration was
recently stressed by Logothetis and Amato (1992). The results
clearly indicate that the AUC of unbound cisplatin and the
DNA-adduct formation in WBC are closely correlated. The
relationship can best be described by a linear relationship
(Figure 2). In addition. the likelihood of a tumour response
was strongly determined by the magnitude of the AUC of
cisplatin (Figures 2 and 3). Not unexpected. because of the
close correlation with the AUC. also the AUA and A__ were
strong predictors of response (Figure 2 and Table II). The
AUC of unbound cisplatin was highly variable, despite the
small dose range of cisplatin of 70-80 mg m-$. Also. in the
two subgroups treated at 70 or 80 mg m-2 the AUC range
was high (Table II). The pharmacokinetic parameters of
cisplatin were of the same magnitude as reported previously
(Himmelstein et al.. 1981: Reece et al.. 1987. 1989). The
highly significant correlation between the AUC and the level
of DNA-adduct formation combined with the strong
predictive power of the AUC gives evidence that the
variability in the dose-response relationship of cisplatin in
our patient population is mainly determined by pharmaco-
kinetic variability. The results were obtained in a hetero-
geneous population with a variety of solid tumours. It implies
that clinical resistance to cisplatin in these tumours is
determined to a substantial extent bv the magnitude of
exposure to unbound cisplatin. We speculate that pharma-
cokinetic variability contributes significantly to clinical
resistance of other tumour types which are potentially
sensitive to cisplatin.
Two DNA-adduct parameters were defined and used
throughout the study: A,,, and AUA. The AUA may
reflect processes leading to induction of DNA-adduct
formation shortly after infusion and DNA repair in the
15 h after infusion of cisplatin. The correlation coefficient
between AUC and AUA (0.78) was slightly higher than
between AUC and A, (0.73). Although the AUA is
theoretically of more interest, the difference in AUA between
responders and non-responders was only marginally greater
than in the A, (Table II). The DNA-adduct levels did not
show a significant accumulation With increasing number of
courses. although the mean of the level during the first course
was slightly lower than during the subsequent courses (Figure
1. Table II). The DNA-adduct levels in responders were
consistently higher than in non-responders throughout the
study (Table II). which supports the results of Reed et al.
(1993). The most reasonable explanation for the overlap in
DNA-adducts and AUC between responders and non-
responders is pharmacodynamic variability.
The relationships between the AUC of cisplatin or DNA-
adduct formation (AUA and Ar,) and the response were
almost similar in the two subgroups treated at 70 or
80 mg m-.
The addition of VP16 had no measurable influence on the
relationship between AUC and DNA-adduct formation or on
the pharmacokinetics of cisplatin. The response rates in the
present study are comparable with those reported by Planting
et al. (1991, 1992, 1993b. 1994).
The weekly schedule was well tolerated overall. Significant
but manageable myelosuppression was encountered. The
AUC and AUA were significantly correlated with the CTC
grade of thrombocytopenia. The nephrotoxicity was manage-
able in almost all patients. No significant correlations were
observed between nephrotoxicity and AUC or DNA-adduct
formation. One-third of the patients developed grade 1
neurotoxicitv. This incidence is of the same order as reported
in previous studies (Cavaletti et al.. 1992: Roelofs et al..
1984). The cumulative AUC of cisplatin was more closely
correlated with the log VPT than the cumulative dose. Of
note. the cumulative dose was not significantly correlated
With any of the neurotoxicity parameters. which is in contrast
to a previous study (Cavaletti et al., 1992). It is important to
note that the AUC of unbound cisplatin was more closely
correlated With any toxicity parameter than the dose.
cumulative dose or dose m-. These relationships. however.
need affirmation in future studies.
The outlined results clearly confirm that a standardised
dose m-' results in wide interpatient variation in the AUC of
cisplatin (Himmelstein et al.. 1981. Reece et al.. 1987. 1989).
Considering the relationship between the AUC and the
likelihood of a tumour response in a population With a
variety of solid tumours. the pharmacokinetic variability has
major implications for the treatment with cisplatin. Patients
should benefit from individualised dosing of cisplatin to
increase the response rate. Based on the si niicant
correlations between AUC and toxicity parameters this will
also lead to more frequent. but mostly predictable. toxicity.
Drug monitoring. applying a limited sampling strategy. is
indicated to achieve target levels of AUC or DNA-adducts.
The present study proVides support for tumour type-specific
trials. for example in non-small-cell lung cancer. This
procedure is currently investigated in a prospective study.
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